Table 1.
Patient distribution according to sex
| Female | Male | Overall | P value | |
|---|---|---|---|---|
| Number | 152 (17.3%) | 729 (82.7%) | 881 (100%) | |
| SAT index, (Median) | 18.6 (0.93–88.09) | 6.19 (0.21–40.48) | 7.03 (0.21–88.09) | <0.001b |
| Mean (±SD), cm2/m2 | 20.04 ± 16.11 | 7.84 ± 6.14 | 9.95 ± 9.85 | |
| SM index, (Median) | 34.30 (14.78–73.05) | 51.74 (8.03–89.06) | 48.56 (8.03–89.06) | <0.001b |
| Mean (±SD), cm2/m2 | 35.32 ± 10.34 | 51.80 ± 13.48 | 48.96 ± 14.41 | |
| BMI (kg/m2), Median | 23.33 (17.10–33.17) | 23.56 (13.87–37.30) | 23.43 (13.87–37.30) | 0.936b |
| Mean (±SD), cm2/m2 | 23.70 ± 3.66 | 23.73 ± 3.58 | 23.72 ± 3.59 | |
| Underweight, n (%) | 7 (4.6%) | 50 (6.9%) | 57 (6.5%) | 0.5911 |
| Normal, n (%) | 95 (62.5%) | 428 (58.7%) | 523 (59.4%) | |
| Overweight, n (%) | 41 (27.0%) | 216 (29.6%) | 257 (29.2%) | |
| Obese, n (%) | 9 (5.9%) | 35 (4.8%) | 44 (5%) | |
| EQD2 Gy (Median) | 72 (64–74) | 72 (64–74) | 72 (64–74) | 0.456b |
| Mean (±SD) | 71.3 ± 1.45 | 71.2 ± 1.56 | 71.26 ± 1.51 | |
| Treatment days (Median) | 52 (44–69) | 52 (39–70) | 52 (39–70) | 0.956b |
| Mean (±SD) | 53.49 ± 4.47 | 53.47 ± 4.73 | 53.48 ± 4.60 | |
| Age (years) Median | 49.51 (19.30–85.55) | 52.12 (26.97–85.22) | 50.81 (19.30–85.55) | <0.001b |
| Mean (±SD) | 49.55 ± 10.86 | 53.25 ± 11.61 | 51.40 ± 11.39 | |
| Lesion, n (%) | ||||
| Nasopharynx | 119 (78.3%) | 323 (44.3%) | 442 (50.2%) | <0.001b |
| Oral cavity | 4 (2.6%) | 41 (5.6%) | 45 (5.1%) | |
| Oropharynx | 23 (15.1%) | 158 (21.7%) | 181 (20.5%) | |
| Hypopharynx | 1 (0.7%) | 146 (20.0%) | 147 (16.7%) | |
| Larynx | 5 (3.3%) | 61 (8.4%) | 66 (7.5%) | |
| T‐Stage, n (%) | ||||
| T2/1 | 103 (67.8%) | 341 (46.8%) | 444 (50.4%) | <0.001b |
| T4/3 | 49 (32.2%) | 388 (53.2%) | 437 (49.6%) | |
| N‐Stage, n (%) | ||||
| N1/0 | 94 (61.8%) | 366 (50.2%) | 460 (52.2%) | 0.009a |
| N3/2 | 58 (38.2%) | 363 (49.8%) | 421 (47.8%) | |
| Chemotherapy, n (%) | ||||
| No | 26 (17.1%) | 89 (12.2%) | 115 (13.1%) | 0.103a |
| Yes | 126 (82.9%) | 640 (87.8%) | 766 (86.9%) | |
| PET study, n (%) | ||||
| No | 20 (13.2%) | 113 (15.5%) | 133 (15.1%) | 0.463a |
| Yes | 132 (86.8%) | 616 (84.5%) | 748 (84.9%) | |
| Smoking, n (%) | ||||
| No | 131 (86.2%) | 160 (21.9%) | 291 (33.0%) | <0.001b |
| Yes | 21 (13.8%) | 569 (78.1%) | 590 (67.0%) | |
| Betel Quid, n (%) | ||||
| No | 144 (94.7%) | 368 (50.5%) | 512 (58.1%) | <0.001b |
| Yes | 8 (5.3%) | 361 (49.5%) | 369 (41.9%) | |
| Alcohol, n (%) | ||||
| No | 134 (88.2%) | 334 (45.8%) | 468 (53.1%) | <0.001b |
| Yes | 18 (11.8%) | 395 (54.2%) | 413 (46.9%) | |
| Comorbidity, n (%) | ||||
| No | 97 (63.8%) | 404 (55.4%) | 501 (56.9%) | 0.057a |
| Yes | 55 (36.2%) | 325 (44.6%) | 380 (43.1%) | |
SAT, subcutaneous fat tissue; SM, skeletal muscle; BMI, body mass index; EQD2 Gy, equivalent dose in 2‐Gy fractions; Gy, gray; PET, positron emission tomography; Index: area/height/height.
a
Chi‐square test.
b
anova.